207 related articles for article (PubMed ID: 37870091)
41. Utility of apparent diffusion coefficient ratios in distinguishing common pediatric cerebellar tumors.
Gimi B; Cederberg K; Derinkuyu B; Gargan L; Koral KM; Bowers DC; Koral K
Acad Radiol; 2012 Jul; 19(7):794-800. PubMed ID: 22513110
[TBL] [Abstract][Full Text] [Related]
42. Available Systemic Treatments and Emerging Therapies for Breast Cancer Brain Metastases.
Rader RK; Anders CK; Lin NU; Sammons SL
Curr Treat Options Oncol; 2023 Jun; 24(6):611-627. PubMed ID: 37071254
[TBL] [Abstract][Full Text] [Related]
43. Disitamab vedotin: a novel antibody-drug conjugates for cancer therapy.
Shi F; Liu Y; Zhou X; Shen P; Xue R; Zhang M
Drug Deliv; 2022 Dec; 29(1):1335-1344. PubMed ID: 35506447
[TBL] [Abstract][Full Text] [Related]
44. Claudin-6 is a nonspecific marker for malignant rhabdoid and other pediatric tumors.
Sullivan LM; Yankovich T; Le P; Martinez D; Santi M; Biegel JA; Pawel BR; Judkins AR
Am J Surg Pathol; 2012 Jan; 36(1):73-80. PubMed ID: 21989342
[TBL] [Abstract][Full Text] [Related]
45. Efficacy, Tolerability, and Pharmacokinetic Studies of Antibody-Drug Conjugates Containing a Low-Potency Pyrrolobenzodiazepine Dimer.
Gregson SJ; Pugh K; Patel N; Afif-Rider S; Vijayakrishnan B; Santos K; Riedl J; Hutchinson I; Kang GD; Chooi KP; Beard R; Adams L; Barry CS; Ball K; Masterson LA; McFarlane M; Hartley JA; Howard PW
Mol Cancer Ther; 2022 Sep; 21(9):1439-1448. PubMed ID: 35793464
[TBL] [Abstract][Full Text] [Related]
46. New Life of Topoisomerase I Inhibitors as Antibody-Drug Conjugate Warheads.
Pommier Y; Thomas A
Clin Cancer Res; 2023 Mar; 29(6):991-993. PubMed ID: 36637483
[TBL] [Abstract][Full Text] [Related]
47. Antibody-drug conjugates transform the outcome of individuals with low-HER2-expression advanced breast cancer.
Qu F; Lu R; Liu Q; Wu X; Huang X; Yin Y; Li W
Cancer; 2024 Apr; 130(S8):1392-1402. PubMed ID: 38271367
[TBL] [Abstract][Full Text] [Related]
48. Antibody-drug conjugates: the evolving field of targeted chemotherapy for breast cancer treatment.
Nader-Marta G; Molinelli C; Debien V; Martins-Branco D; Aftimos P; de Azambuja E; Awada A
Ther Adv Med Oncol; 2023; 15():17588359231183679. PubMed ID: 37435563
[TBL] [Abstract][Full Text] [Related]
49. Antibody-Drug Conjugates for Cancer Treatment.
Lambert JM; Berkenblit A
Annu Rev Med; 2018 Jan; 69():191-207. PubMed ID: 29414262
[TBL] [Abstract][Full Text] [Related]
50. Antibody-Drug Conjugates in Gynecologic Cancer.
Karpel HC; Powell SS; Pothuri B
Am Soc Clin Oncol Educ Book; 2023 May; 43():e390772. PubMed ID: 37229642
[TBL] [Abstract][Full Text] [Related]
51. Development and biological assessment of MMAE-trastuzumab antibody-drug conjugates (ADCs).
Yaghoubi S; Gharibi T; Karimi MH; Sadeqi Nezhad M; Seifalian A; Tavakkol R; Bagheri N; Dezhkam A; Abdollahpour-Alitappeh M
Breast Cancer; 2021 Jan; 28(1):216-225. PubMed ID: 32889587
[TBL] [Abstract][Full Text] [Related]
52. Evaluation of Quantitative Relationship Between Target Expression and Antibody-Drug Conjugate Exposure Inside Cancer Cells.
Sharma S; Li Z; Bussing D; Shah DK
Drug Metab Dispos; 2020 May; 48(5):368-377. PubMed ID: 32086295
[TBL] [Abstract][Full Text] [Related]
53. [New treatment options for metastatic HER2-low breast cancer : Consequences for histopathological diagnosis].
Denkert C; Lebeau A; Schildhaus HU; Jackisch C; Rüschoff J
Pathologie (Heidelb); 2022 Nov; 43(6):457-466. PubMed ID: 36227345
[TBL] [Abstract][Full Text] [Related]
54. Uncovering therapeutic opportunities in the clinical development of antibody-drug conjugates.
Nieto-Jiménez C; Sanvicente A; Díaz-Tejeiro C; Moreno V; Lopez de Sá A; Calvo E; Martínez-López J; Pérez-Segura P; Ocaña A
Clin Transl Med; 2023 Sep; 13(9):e1329. PubMed ID: 37740463
[TBL] [Abstract][Full Text] [Related]
55. A novel anti-HER2 anthracycline-based antibody-drug conjugate induces adaptive anti-tumor immunity and potentiates PD-1 blockade in breast cancer.
D'Amico L; Menzel U; Prummer M; Müller P; Buchi M; Kashyap A; Haessler U; Yermanos A; Gébleux R; Briendl M; Hell T; Wolter FI; Beerli RR; Truxova I; Radek Š; Vlajnic T; Grawunder U; Reddy S; Zippelius A
J Immunother Cancer; 2019 Jan; 7(1):16. PubMed ID: 30665463
[TBL] [Abstract][Full Text] [Related]
56. Novel development strategies and challenges for anti-Her2 antibody-drug conjugates.
Zhang X; Huang AC; Chen F; Chen H; Li L; Kong N; Luo W; Fang J
Antib Ther; 2022 Jan; 5(1):18-29. PubMed ID: 35146330
[TBL] [Abstract][Full Text] [Related]
57. HER2 Low Breast Cancer: A New Subtype or a Trojan for Cytotoxic Drug Delivery?
Popović M; Silovski T; Križić M; Dedić Plavetić N
Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37175916
[TBL] [Abstract][Full Text] [Related]
58. Trastuzumab-monomethyl auristatin E conjugate exhibits potent cytotoxic activity in vitro against HER2-positive human breast cancer.
Abdollahpour-Alitappeh M; Lotfinia M; Bagheri N; Sineh Sepehr K; Habibi-Anbouhi M; Kobarfard F; Balalaie S; Foroumadi A; Abbaszadeh-Goudarzi G; Abbaszadeh-Goudarzi K; Abolhassani M
J Cell Physiol; 2019 Mar; 234(3):2693-2704. PubMed ID: 30246298
[TBL] [Abstract][Full Text] [Related]
59. The HER2-low revolution in breast oncology: steps forward and emerging challenges.
Nicolò E; Boscolo Bielo L; Curigliano G; Tarantino P
Ther Adv Med Oncol; 2023; 15():17588359231152842. PubMed ID: 36844387
[TBL] [Abstract][Full Text] [Related]
60. Common pediatric cerebellar tumors: correlation between cell densities and apparent diffusion coefficient metrics.
Koral K; Mathis D; Gimi B; Gargan L; Weprin B; Bowers DC; Margraf L
Radiology; 2013 Aug; 268(2):532-7. PubMed ID: 23564715
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
